Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A new method is developed to track dormant HIV-infected cells. This breakthrough may lead to new treatments that eliminate ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Efavirenz, an HIV drug, shows potential for treating chikungunya virus, inhibiting replication and reducing viral load ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...